Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining tipifarnib with radiation therapy in
treating patients who have newly diagnosed glioblastoma multiforme. Tipifarnib may stop the
growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Radiation
therapy uses high-energy x-rays to damage tumor cells. Combining tipifarnib with radiation
therapy may make the tumor cells more sensitive to radiation therapy and may kill more tumor
cells.